Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. [electronic resource]
Producer: 20100830Description: 3051-4 p. digitalISSN:- 1791-7530
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Capecitabine
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Docetaxel
- Female
- Fluorouracil -- administration & dosage
- Humans
- Middle Aged
- Neoplasm Metastasis
- Prospective Studies
- Receptor, ErbB-2 -- biosynthesis
- Receptors, Estrogen -- biosynthesis
- Receptors, Progesterone -- biosynthesis
- Taxoids -- administration & dosage
- Trastuzumab
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.